Utrata całkowitej odpowiedzi cytogenetycznej po odstawieniu nilotynibu

Abstract

The achievement of treatment-free remission (TFR) became recently a new, important goal of \nchronic myelogenous leukemia (CML) therapy. The strategy to achieve durable, deep molecular \nresponse, and, subsequently, to discontinue tyrosine kinase inhibitor (TKI) is particularly attractive \nfor younger patients, and for those, who experience long-lasting side effects that reduce substantially \nthe quality of life. The results of many clinical trials suggest that approximately 50% of patients \ncan achieve durable TFR. In the remaining patients, loss of major molecular response (and less \nfrequently complete cytogenetic response [CCyR]) is the cause of treatment reintroduction. Discontinuation \nof TKI is considered a safe procedure. No disease progressions or deaths caused by \ntreatment discontinuation were noted so far. Here, we present a case of a patient who lost a CCyR \nafter discontinuation of nilotinib. The reintroduction of nilotinib resulted in the rapid achievement \nof CCyR and DMR (MR4).